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Vincristine-Induced Cranial Neuropathy
Abstract
Vincristine (VCR) is a vinca alkaloid that is used for treatment of many 
malignancies.
The vinca alkaloids are neurotoxic, usually causing a peripheral neuropathy, but 
cranial neuropathies are rare as side effects.
Described here is the case of a 2.5-year-old boy, a known case of Wilms’ tumor, 
treated by vincristine (0.067 mg/kg/day) and dactinomycin (0.045 mg/kg/day) 
after surgery. Three weeks after treatment, he presented with bilateral ptosis. 
Neurological examination revealed bilateral ptosis with normal pupillary reflex 
and eye movement. He received 3.015 mg cumulative dose of vincristine before 
development of ptosis.
Treatment with pyridoxine (150 mg/m2 p.o. BID) and pyridostigmine (3 mg/kg 
p.o. BID) was started as neuroprotective agents, and after 7 days the problem 
disappeared.
The treatment continued for 6 weeks and there were no signs of ptosis or a 
recurrence in follow up 2 months later.
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CASE REPORT
Introduction
Vincristine (VCR) is a vinca alkaloid used for treatment of many malignancies such 
as acute lymphoblastic leukemia, neuroblastoma, Ewing’s sarcoma, Wilms’ tumor, 
rhabdomyosarcoma, Hodgkin’s disease, non-Hodgkin’s lymphoma (1), idiopathic 
thrombocytopenic purpura, and autoimmune hemolytic anemia (2).
Neurotoxicity is a well-known side effect of VCR that was first reported in 1967. 
VCR results in axonal degeneration and delay in distal axon transportation. Since 
VCR has low central nervous system (CNS) penetration, the neurological side 
effects frequently manifest in the peripheral nervous system (3).
The standard dose of VCR is 1-2 mg/m2 once every 1-3 weeks and consumption 
of doses over 2 mg is neurotoxic, especially as a weekly prescription.Therefore, 
multiple regimes are needed to decrease the neurotaxic effect (1).
Vincristine induced neurotoxicity can be divided into four groups:
1. Peripheral neuropathy
2. Autonomic neuropathy 
3. Encephalopathy
4. Cranial neuropathy
The most common side effect is dose-dependent peripheral neuropathy with early 
depression of the deep-tendon reflexes. Other known side effects are paresthesia, 
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liver function, history of peripheral neuropathy, and 
simultaneous consumption of drugs like Methotrexate, 
L-asparginas, allopurinol, erythromycin, INH, 
mitomycin-C, phenytoin, or itraconazole (5).
Treatment by VCR may result in encephalopathy, 
seizure, or SIADH.
Consumption of 5-6 mg VCR in most patients reveals 
early signs of toxicity, but remarkable toxicity is not 
seen in cumulative doses less than 15-20 mg (6).
The definitive diagnosis of VCR induced neuropathy 
is related to the exclusion of other etiologies that cause 
similar clinical features.
Findings in the present case that support a diagnosis of 
VCR induced neuropathy are:
1-  the time course of ptosis after treatment;
2-  the absence of pathologic findings in CSF analysis 
and MRI;
3-  The resolution of ptosis after treatment.
There are no entirely convincing reports of effective 
pharmacologic measures to prevent or to treat vincristine 
induced neuropathy, apart from a few case reports of 
cranial neuropathy that was treated with pyridoxine and 
pyridostigmine (2). 
Whether the VCR-induced neuropathy is recovered by 
pyridoxine is still unknown.
For the first time, pyridoxine was used for Isoniazid-
induced neuropathy treatment in tuberculosis patients. 
Isoniazid (INH) neuropathy results from pyridoxine 
consumption and its deficiencies (3).
Neuroprotective pyridoxine effects on VCR-induced 
neuropathy in animal models showed promise, but its 
useful effects on humans remain unproven (3).
In a study of 24 patients suffering from stage II breast 
cancer under adjuvant chemotherapy with VCR, 1.5 gm 
of pyridoxine was administrated daily for 6 weeks, but 
treatment was not effective. However, the high-dose 
of pyridoxine used in this study has previously been 
reported to cause neuropathy by itself in the absence 
of VCR, which casts doubt as to the etiology of the 
neurological symptoms and the negative results (3).
In a case report published in a leukemia research journal, 
a 21-year-old patient suffering from ALL, after afflicted 
4 times of chemotherapy with dysphagia, dysarthria, and 
an inability to open the mouth wide enough to eat. A 
physical exam showed bilateral 7 and 12 nerve palsy and 
gait disorder, cranial nerve palsies, and brain dysfunction 
in most advanced cases (4).
Case Report
A 2.5-year-old boy with a known case of Wilms’ tumor 
was treated by VCR (0/067 mg/kg/day) and dactinomycin 
(0/045 mg/kg/day) after surgery. Three weeks after 
treatment, he presented with bilateral ptosis. There was 
no companying symptom in the patient history.
There was no trauma, recent eye surgery, or neurological 
disease in the patient medical history. Past drug history 
included only chemotherapy drugs. There were no 
positive points in the family history as well. There was 
nothing found in the physical exam, except for bilateral 
ptosis. Pupil reflex and eye movement were normal 
(fig1).
Laboratory data such as, LFT, CBC, and electrolytes 
were normal.
We had suspicions of a brain lesion and an MRI was 
ordered, but the MRI and the ensuing lumbar puncture 
were also normal.
Because the etiology of ptosis was unknown in 
evaluations and it is known as a side effect from VCR 
treatment, treatment by pyridoxine (150 mg/m2 p.o.BID), 
and pyridostigmine (3 mg/kg p.o.BID) were started 
as neuroprotective agents. After 7 days the problem 
disappeared.
The treatment continued for 6 weeks and there were no 
signs of ptosis or a recurrence in follow up visits over the 
next 2 months.
Discussion
Vincristine (VCR) is a vinca alkaloid and neurotoxicity 
is a well-known side effect of VCR (3).
Signs of VCR induced neuropathy usually appear in 2-19 
weeks after treatment (5). The clinical manifestation of 
VCR induced neurological complications are paresthesia, 
ataxia, gait disorder, wrist and foot drop, depression of 
DTR, facial nerve palsy, weakness, optic neuropathy (1), 
transient cortical blindness, ptosis, abdominal colic pain, 
constipation, urinary retention, orthostatic hypotension, 
jaw pain, hoarseness, and loss of sensory neural hearing 
(6). 
The incident rate of these complications is dependent on 
age, VCR dose, treatment duration, nutritional condition, 
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Fig 1. Physical exam showed the patient had bilateral ptosis with normal pupil reflex and eye movement.
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loss of tongue movement. Up to that point, a cumulative 
dose of VCR in the patient was 2mg /m2 (actual dose: 
28mg). Finally, after exclusion of other causes, patient 
was diagnosed with VCR-induced neuropathy and 
was treated with pyridoxine 150mg/m2 daily(total dose 
250mg), after 5 days the symptoms disappeared and 
after 2 weeks there was a complete recovery.
Table 1 indicates other case reports regarding VCR-
induced neuropathy with successful treatments of 
pyridoxine and prydostigmine (Table 1)(5,7-10).
Another case report was published in the Indian Journal 
of Pediatrics, in which a 5-year-old girl was described 
who suffered from ALL and was under chemotherapy 
treatment with VCR, L-asparaginase, prednisolone, and 
daunorubicin.  Five days after the fourth dose of VCR 
was administered, bilateral ptosis appeared. Further sur-
veys were in favor of VCR-induced neuropathy in this 
patient as well.
The patient was treated with pyridoxine (150 mg/ m2.p.o 
BID) and pyridostigmine (3 mg/ kg.P.O BID) and she 
recovered after 7 days and completely recovered after 2 
weeks (5).
According to the aforementioned reports and patients, 
it seems that the application of pyridoxine and 
pyridostigmine can be successfully used in patients with 
VCR-induced neuropathy.
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